Physician profile
Sunil Nayyar
NPI 1972763852
$71,613.70
in general payments reported to CMS, 2019-2025
56 companies · $8,914 in 2025
The $8,914 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,843 · 2020: $4,034 · 2021: $6,372 · 2022: $18K · 2023: $16K · 2024: $13K · 2025: $8,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $1,102 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,778.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,700.00 |
| Travel and Lodging | $1,102.30 |
| Education | $435.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,040.17 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $9,015.97 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Amgen INC. | $2,192.69 | 2019-2025 | Otezla, Repatha, Otezla |
| Bausch Health US, LLC | $2,134.36 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $1,813.67 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $1,769.81 | 2023-2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $1,730.51 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $1,652.87 | 2019-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,448.15 | 2019-2025 | Relistor, Trulance, Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,362.79 | 2022-2025 | Caplyta |
| Allergan, INC. | $1,306.09 | 2019-2021 | |
| Gilead Sciences, INC. | $1,261.94 | 2019-2024 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $1,017.37 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lilly USA, LLC | $705.39 | 2019-2025 | Mounjaro, Zepbound |
| Braeburn INC. | $609.05 | 2023-2025 | Brixadi |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Nayyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.